



Luxembourg, 21 April 2022

**Scientific Committee on Health, Environmental and Emerging Risks SCHEER**  
**Working Group on "Draft Environmental Quality Standards for Priority Substances under the Water Framework Directive" and on "groundwater quality standards for proposed additional pollutants in the annexes to the Groundwater Directive (2006/118/EC)".**

6 April 2022, Luxembourg

**Minutes**

**1. Welcome and apologies, approval of the agenda and declaration of interests**

The Chair welcomed the participants. Two apologies were received.

The agenda was adopted without changes.

The Chair invited participants to declare any interest regarding matters on the agenda.

None of the participants declared any new interest related to the matters on the agenda

**2. List of points discussed**

Commission (COM) participated in the first hour meeting to present the new mandates/dossiers on Hexachlorobenzene and Hexachlorobutadiene, as well as their comments on a preliminary opinion.

**2.1. Subgroup for Groundwater Directive**

The comments received on the preliminary Opinion on Groundwater will be discussed during the next WG meeting.

**2.2. Subgroup for priority substances under the Water Framework Directive**

The preliminary Opinion on diclofenac was discussed and COM participated in the discussion to clarify some issues. The preliminary Opinion on clarithromycin is still under clarification with COM as well. The preliminary Opinion on chlorpyrifos has been presented and will be further discussed in the next WG meeting.

The preliminary Opinion, on PFAS has been published for comment until 6 May 2022: [SCHEER - Opinions \(europa.eu\)](https://europa.eu/scheer/opinions)

The comments received on neonicotinoids have been adopted in plenary meeting and final opinions published: [SCHEER - Opinions \(europa.eu\)](https://europa.eu/scheer/opinions)

The comments received on pyrethroids have been adopted in plenary meeting but final opinions will be published together, as soon as the last updated dossier received will be taken into account.

The comments received on preliminary Opinion on antibiotic macrolide azithromycin have been discussed and SCHEER responses are planned to be finalised during the next WG meeting.

**3. Any Other Business**

Next meetings are planned on 26 April, 13 & 20 May, 14 & 27 June, 6 & 25 July 2022.